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and ‡Royal Brompton Hospital, London, United Kingdom.BACKGROUND Patients with a variety of clinical presentations
undergo atrial ﬁbrillation (AF) ablation. Long-term ablation success
rates can vary considerably.
OBJECTIVE The purpose of this study was to develop a clinical
scoring system to predict long-term freedom from AF after ablation.
METHODS We retrospectively derived the scoring system on a
development cohort (DC) of 1125 patients undergoing AF ablation
and tested it prospectively in a test cohort (TC) of 937 patients
undergoing AF ablation.
RESULTS The demographics of the DC patients were as follows: age
62.3± 10.3 years, male sex 801 (71.2%), left atrial size 4.30± 0.69
cm, paroxysmal AF 348 (30.9%), number of drugs failed 1.3 ± 1.1,
hypertension 525 (46.7%), diabetes 100 (8.9%), prior stroke/
transient ischemic attack 78 (6.9%), prior cardioversion 528
(46.9%), and CHADS2 score 0.87 ± 0.97. Multivariate analysis
showed 6 independent variables predicting freedom from AF after
ﬁnal ablation: coronary artery disease (P ¼ .021), atrial diameter
(P ¼ .0003), age (P ¼ .004), persistent or long-standing AF (Po
.0001), number of antiarrhythmic drugs failed (P o .0001), and
female sex (P ¼ .0001). We created a scoring system (CAAP-AF)
using these 6 variables, with scores ranging from 0 to 13 points.Dr Winkle serves as an investigator for ARCA biopharma. Dr Mead and
Dr Engel serve as consultants to Medtronic. Dr Kong serves on the advisory
board of Medtronic. Address reprint requests and correspondence: Dr
Roger A.Winkle, Silicon Valley Cardiology, 1950 University Avenue, Suite
160, E. Palo Alto, CA 94303. E-mail address: rawinkle@aol.com.
1547-5271/$-see front matter B 2016 The Authors. Published by Elsevier Inc. on
10.1016/j.hrthm.2016.07.018The 2-year AF-free rates by CAAP-AF scores were as follows: 0 ¼
100%, 1 ¼ 95.7%, 2 ¼ 96.3%, 3 ¼ 83.1%, 4 ¼ 85.5%, 5 ¼ 79.9%,
6¼ 76.1%, 7¼ 63.4%, 8¼ 51.1%, 9¼ 53.6%, and ≥10¼ 29.1%.
Ablation success decreased as CAAP-AF scores increased (P o
.0001). The CAAP-AF score also predicted freedom from AF in the
TC. The 2-year Kaplan-Meier AF-free rates by CAAP-AF scores were as
follows: 0¼ 100%, 1¼ 87.0%, 2¼ 89.0%, 3¼ 91.6%, 4¼ 90.5%,
5 ¼ 84.4%, 6 ¼ 70.1%, 7 ¼ 71.0%, 8 ¼ 60.7%, 9 ¼ 68.9%, and
≥10 ¼ 51.3%. As CAAP-AF scores increased, 2-year freedom from
AF in the TC decreased (P o .0001).
CONCLUSION An easily determined clinical scoring system was
derived retrospectively and applied prospectively. The CAAP-AF
score predicted freedom from AF after ablation in both a DC and
a TC of patients undergoing AF ablation. The CAAP-AF score
provides a realistic AF ablation outcome expectation for individual
patients.
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Catheter ablation of atrial ﬁbrillation (AF) can be effective
for restoring sinus rhythm in many patients.1–4 However, not
all patients have sinus rhythm restored by ablation and there
can be both early and late relapses to AF in many patients.2
The percentage of patients maintaining sinus rhythm after
ablation can vary widely, from as high as 90% to as low as
29%.3–5 Retrospective analyses of outcome data have
identiﬁed a number of independent clinical variables related
to ablation success or failure. Ablation failure after single or
multiple ablation procedures has been correlated with largerleft atrial (LA) size,3,4,6 persistent vs paroxysmal AF,3,4,7 AF
duration,6 older age of patients at the time of ablation,7,8
female sex,9 number of antiarrhythmic drugs failed before
ablation,10,11 higher CHADS2 and CHA2DS2-VASc
scores,12–14), and the presence of hypertension,3,15 untreated
obstructive sleep apnea,16 coronary artery disease (CAD),4
and metabolic syndrome.17 Because AF ablation is an
expensive procedure and is associated with a small but
deﬁnite risk of serious complications, it would be desirable to
estimate outcomes before embarking on an AF ablation
strategy. In this study, we retrospectively develop a simple
and inexpensive scoring system to predict ablation outcomes
on the basis of clinical variables in a population of patients
undergoing ablation therapy. We then prospectively evaluate
the score’s ability to predict the outcome in a separate and
subsequent population of patients undergoing AF ablation.behalf of Heart Rhythm Society. All rights reserved. http://dx.doi.org/
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Patient population
The participants were consecutive symptomatic patients
undergoing AF ablation at Sequoia Hospital, Redwood City,
CA, from October 10, 2003, to December 31, 2012. All
signed written informed consent. Patients were divided into 2
groups: a development cohort (DC) of 1125 consecutive
patients undergoing initial ablation from 2003 to 2010 and a
test cohort (TC) of 937 patients undergoing initial AF
ablation from 2010 to 2012.
Data were collected prospectively, and analysis was per-
formed retrospectively and approved by the Western Institu-
tional Review Board. AF type was categorized as paroxysmal:
lastingo1 week; persistent: lasting41 week ando1 year or
requiring pharmacological or electrical cardioversion in o1
week; and long-standing persistent: lasting41 year.
Ablation protocol
Our ablation protocol has been previously described.4 Antiar-
rhythmic drugs were discontinued at least 5 half-lives and
amiodarone at least 3 months before ablation. The NavX
system (St. Jude Medical, Inc., Saint Paul, MN) or CARTO
systems (Biosense Webster Inc., Diamond Bar, CA) were used
for 3-dimensional mapping in all cases. Before January 2006,
we used a closed-tip catheter; and after January 2006, an open-
irrigated tip catheter. After July 2006, all irrigated-tip catheter
ablation procedures were performed using 50 W for short
durations (generally o10 seconds) at each site,18,19 including
the posterior wall. All patients underwent circumferential
pulmonary vein isolation and linear ablation of the LA roof.
Patients with right or LA isthmus ﬂutter underwent linear
ablation of the cavotricuspid and/or mitral isthmus. Patients
with persistent AF had low posterior LA lines and LA complex
fractionated electrograms ablated. Some patients with long-
standing persistent AF underwent additional ablation within the
coronary sinus (at 30–35 W), ablation of complex right atrial
fractionated electrograms, and/or superior vena cava isolation.
Isoproterenol was given, and nonpulmonary vein triggers were
mapped and ablated. Repeat ablation procedures were not
performed until at least 3 months after initial ablation.
Data collection and analysis
For each patient we recorded preablation age, sex, duration
of AF (deﬁned as time from the ﬁrst clinical episode of AF to
the time of ﬁrst ablation), AF type, prior antiarrhythmic drug
therapy, CHADS2 and CHA2DS2-VASc scores, cardiover-
sions, body mass index, LA size measured on a preablation
transthoracic echocardiogram in the parasternal long-axis
view, prior cerebral vascular accidents/transient ischemic
attacks, and the presence of hypertension, diabetes, CAD,
cardiomyopathy, and obstructive sleep apnea.
Follow-up
Some patients were treated with antiarrhythmic drugs and/or
cardioverted during the ﬁrst 3 months after ablation. Patients
sent daily transtelephonic electrocardiographic (ECG) strips for1–3 months after ablation and were seen at 3 and 12 months at
which time continuous monitoring consisted of 24- to 48-hour
ECG recording before 2006 and of 7- to 14-day ECG recording
thereafter. Patients were seen or contacted frequently from 3 to
12 months. Thereafter, patients were seen directly or contacted
by phone at least annually and arrhythmia records obtained
from hospitals and referring physicians. ECG recorders were
reissued for any arrhythmia symptoms. Pacemaker AF data
were used when available. Patients were taught to check their
pulse daily and to use pulse oximeters, ﬁtness monitors, or
smartphone apps when unable to feel their pulse. A successful
ablation was deﬁned as no AF, ﬂutter, or tachycardia lasting
more than 30 seconds off antiarrhythmic drugs after a 3-month
blanking period. Initial failures were encouraged to undergo
repeat ablation after the 3-month blanking period.
Statistical analysis
Statistical analysis was performed using XLSTAT 2014
(XLSTAT Paris, France). Continuous data are presented as
mean± SD and categorical data as counts and percentages. The
Student t test and χ2 test were used to compare clinical
characteristics and variables between the DC and the TC.
Multivariate Cox regression analysis was employed for the DC
using 14 clinical variables to identify independent predictors of
ablation freedom from AF after ﬁnal ablation. For each of the
independent predictors of freedom from AF after ﬁnal ablation
Kaplan-Meier curves were generated for AF-free survival on
the basis of the presence or absence of the variable for discrete
variables (AF type, sex, presence of CAD, and number of
antiarrhythmic drugs failed) or by ranges for the continuous
variables (age and LA size). Based on the degree of separation
of the Kaplan-Meier curves over time, an empirically derived
point–based weighting scheme was developed. The variables
with the largest separation on the Kaplan-Meier curves over
time were given the highest number of points in the scoring
system. The CAAP-AF acronym stands for the presenceor
absence of CAD, the left Atrial diameter, Age, the presence of
Persistent or long-standing AF, the number of Antiarrhythmic
drugs failed, and Female sex. The CAAP-AF score (range 0–13
points) is the sum of the points assigned to the 6 weighted
independent variables predicting postablation freedom from
AF. This score was then applied prospectively to the TC to see
how it performed in a new cohort of patients undergoing AF
ablation. The C statistic was calculated for both the DC and the
TC. Cochran-Armitage trend analysis was performed on the 2-
year AF ablation success rates as a function of CAAP-AF score
for both the DC and the TC. All tests were 2-sided, andPo .05
was considered statistically signiﬁcant.
Results
Patient population
The patient population consisted of 2 cohorts of patients
undergoing AF ablation. The DC consisted of 1125 patients
undergoing AF ablation from 2003 to 2010. The DC was used
for retrospective evaluation and development of the CAAP-AF
scoring system to predict the patient’s freedom from AF after
Table 1 Comparison of clinical characteristics between the
development and test cohorts
Characteristic
Development
cohort Test cohort P
No. of patients 1125 937 NA
Age (y) 62.3 ± 10.3 64.9 ± 9.3 o.0005*
Sex: female 324 (28.8%) 299 (31.9%) .135
Duration of AF (y) 6.4 ± 7.0 6.3 ± 7.6 .599
No. of drugs failed 1.30 ± 1.05 1.25 ± 1.05 .283
Left atrial size (cm) 4.30 ± 0.69 4.27 ± 0.68 .322
CHADS2 score 0.88 ± 0.97 1.49 ± 1.14 o.0005*
CHA2DS2-VASc score 1.60 ± 1.34 2.00 ± 1.44 o.001*
Hypertension 525 (46.7%) 572 (61.0%) o.0005*
Diabetes 100 (8.9%) 135 (14.4%) o.0005*
Body mass index (kg/m2) 29.5 ± 5.4 29.1 ± 5.7 .087
Paroxysmal AF 348 (30.9%) 296 (31.6%) .738
Persistent AF 594 (52.8%) 552 (58.8%) .007*
Long-standing AF 183 (16.3%) 89 (9.4%) o.0005*
Prior cardioversion 528 (46.9%) 442 (47.2%) .914
Coronary artery disease 150 (13.3%) 150 (16.0%) .103
Dilated cardiomyopathy 91 (8.1%) 109 (11.6%) .007*
Obstructive sleep apnea 118 (10.5%) 193 (20.6%) o.0005*
Prior stroke/TIA 78 (6.9%) 75 (8.0%) .399
Values are presented as mean ± SD or as n (%)
AF ¼ atrial ﬁbrillation; TIA ¼ transient ischemic attack.
* ¼ statistically signiﬁcant.
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consisted of 937 patients undergoing AF ablation from 2010 to
2012. The CAAP-AF scoring system developed on the DC
was applied to the TC to evaluate its ability to predict freedom
from AF in a separate group of patients undergoing AF
ablation. Table 1 shows the clinical characteristics of the DC
compared with those of the TC. There were moderate differ-
ences between the 2 cohorts. The TC was older (64.9 ± 9.3
years vs 62.3 ± 10.3 years; P o .005), had higher CHADS2
scores (1.49 ± 1.14 vs 0.88 ± 0.97; P o .0005) and
CHA2DS2-VASc scores (2.00 ± 1.44 vs 1.60 ± 1.34; P o
.0001), had more persistent AF (58.8% vs 52.8%; P ¼ .007),
had less long-standing persistent AF (9.4% vs 16.3%; P o
.0005), and had more hypertension (61% vs 46.7%; P o
.0005), diabetes (14.4% vs 8.9%; P o .005), dilated cardio-
myopathies (11.6% vs 8.1%; P ¼ .007), and obstructive sleep
apnea (20.6% vs 10.5%; P o .0005). These clinical differ-
ences most likely represent broader patient selection for AF
ablation, as older patients with more comorbidities have been
ablated in later years compared with earlier years.Evaluation of the TC
The 14 clinical variables evaluated as possible predictors of
freedom from AF after the ﬁnal ablation in the DC are listed
in Table 2. The average duration of follow-up at the time the
CAAP-AF score was developed for these 1125 patients was
2.5 ± 1.7 years. Multivariate analysis showed that 6 of these
14 variables were independent predictors of long-term free-
dom from AF. These included age, LA size, sex, paroxysmal
vs persistent/long-standing AF, the number of previous
antiarrhythmic drugs failed, and the presence or absence of
coronary heart disease. Repeat multivariate analysis usingthese 6 variables alone indicated that all remained statisti-
cally signiﬁcant independent predictors of long-term free-
dom from AF after ﬁnal AF ablation.
Development of the CAAP-AF score
Kaplan-Meier curves for each independent predictor of long-term
freedom from AF were evaluated. Figure 1 shows an example of
the separation of the Kaplan-Meier curves over time for 3 of the
clinical predictors. The presence of CAD (Figure 1A) reduced
long-term freedom from AF after ﬁnal ablation by 13% from
69% to 56%. The presence of CAD was assigned 1 point in the
CAAP-AF scoring system. The presence of persistent or long-
standing persistent AF compared with paroxysmal AF
(Figure 1B) reduced long-term freedom from AF after ﬁnal
ablation by 23% from 83% to 60%. The presence of persistent or
long-standing AF was assigned 2 points in the CAAP-AF score.
The presence of a progressively larger left atrium (Figure 1C)
reduced long-term freedom from AF after ﬁnal ablation by 30%
from 77% to 47%. LA size was assigned up to 4 points in the
CAAP-AF score. Similarly, points were assigned to the other 3
variables as 1 point for female sex, up to 2 points for more
antiarrhythmic drugs failed, and up to 3 points for older age. This
ﬁnal CAAP-AF score is shown in Figure 2. The CAAP-AF
acronym stands for the presence or absence of CAD, the left
Atrial diameter, Age, the presence of Persistent or long-standing
AF, the number of Antiarrhythmic drugs failed, and Female sex.
The CAAP-AF score can range from 0 to 13 points.
Freedom from AF based on the CAAP-AF
score in the DC
Table 3 shows freedom from AF after ﬁnal AF ablation at the
time of follow-up by each CAAP-AF score in the DC. There
was a decrease in the percentage of patients free from AF as
the CAAP-AF score increased, which was found to be
statistically signiﬁcant by using the Cochran-Armitage trend
test (P o .0001).
Because of the small number of patients in the low and
high CAAP-AF score groups, Kaplan-Meier curves were
created for ranges of CAAP-AF scores and are shown in
Figure 3A. This shows a 4-year freedom from AF of ~85%
for those patients with the lowest CAAP-AF scores and a
o50% freedom from AF for those with the highest CAAP-
AF scores. The C statistic for the CAAP-AF score was 0.691
(Figure 4A).
Prospective evaluation in the TC
The average duration of follow-up for these 937 patients was
1.8 ± 0.9 years. Table 3 shows freedom from AF after ﬁnal
AF ablation at the time of follow-up by each CAAP-AF
score in the TC. An increase in CAAP-AF scores was
associated with a decrease in the percentage of patients free
from AF, which was found to be statistically signiﬁcant by
using the Cochran-Armitage trend test (Po .0001). Because
of the small number of patients in the low and high CAAP-
AF score groups, Kaplan-Meier curves were created for
ranges of CAAP-AF scores and are shown in Figure 3B. This
Table 2 Multivariate Cox regression analysis of factors affecting AF recurrence in the development cohort after ≥1 AF ablation procedures
(ie, ﬁnal outcome)
Variable Hazard ratio Hazard ratio 95% Boundary P
Age 1.024 1.011–1.038 .0044*
Left atrial size 1.421 1.175–1.718 .00029*
Sex: male vs female 0.492 0.381–0.635 o.0001*
Paroxysmal vs persistent/long-standing AF 0.389 0.255–0.594 o.0001*
No. of antiarrhythmic drugs failed 1.223 1.105–1.354 o.0001*
Coronary disease (present vs absent) 1.443 1.057–1.970 .021*
AF duration 1.007 0.992–1.023 .374
Obstructive sleep apnea 1.272 0.877–1.844 .205
Dilated cardiomyopathy 1.468 0.953–2.261 .082
NYHA functional class 0.917 0.766–1.097 .342
Prior cardioversion 1.139 0.725–1.277 .790
Body mass index 0.991 0.968–1.015 .479
Hypertension (present vs absent) 0.920 0.721–1.172 .498
Diabetes (present vs absent) 1.204 0.824–1.579 .338
AF ¼ atrial ﬁbrillation; NYHA ¼ New York Heart Association.
*Statistically signiﬁcant.
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with the lowest CAAP-AF scores to just over 60% for those
with the highest CAAP-AF scores. The C statistic for the
CAAP-AF score was 0.650 (Figure 4B).Comparison of the DC and the TC
Because of the different time of follow-up in the 2 cohorts,
we compared the AF-free rate at 2 years between the DC and
the TC (Figure 5). Both cohorts show a decline in freedom
from AF with an increase in CAAP-AF scores. The TC has a
slightly higher rate of freedom from AF than does the DC,
probably because of technological improvements and oper-
ator experience over time.Repeat ablation
Although there was a modest increase in the average number
of ablation procedures performed per patient with higher
CAAP-AF scores in both the DC (ranging from 1.23 ± 0.44
ablation procedures for scores 0–3 and 1.37 ± 0.55 ablation
procedures for scores ≥8) and the TC (ranging from 1.17 ±
0.41 ablation procedures for scores 0–3 and 1.27 ± 0.4Figure 1 Kaplan-Meier curves for freedom from AF after ﬁnal AF ablation by
size (C). Parameters associated with larger separation of the Kaplan-Meier curve
CAAP-AF ¼ presence or absence of coronary artery disease, left atrial diameter
antiarrhythmic drugs failed, and female sex; CAD ¼ coronary artery disease; LAablation procedures for scores ≥8), this did not reach
statistical signiﬁcance in either the DC or the TC.Discussion
The main ﬁnding of this study is that based on simple and
easily obtained clinical variables that are available before any
ablation is performed, it is possible to develop a clinical
scoring system that predicts long-term freedom from AF after
ablation. When applied prospectively to a new population of
patients undergoing AF ablation, this score was also able to
predict long-term freedom from AF after ablation.
All the individual clinical variables that proved to be
independent predictors of ablation success have been pre-
viously reported to inﬂuence AF ablation outcome. LA size
is the most commonly cited predictor of ablation outcome.
Numerous studies3,4,6 have shown that larger LA size is
associated with poorer long-term outcome of AF ablation.
Persistent AF has also been shown in almost all studies to be
associated with a poorer long-term outcome after ablation
when compared with paroxysmal AF.3,4,6 Older age,7,8 female
sex,9 and the presence of CAD4 have also all been shown topresence or absence of CAD (A), by type of AF (B), and by ranges of LA
s were given more weight in the CAAP-AF score. AF ¼ atrial ﬁbrillation;
, age, presence of persistent or long-standing atrial ﬁbrillation, number of
¼ left atrial.
Figure 2 CAAP-AF score. CAAP-AF ¼ presence or absence of coronary
artery disease, left atrial diameter, age, presence of persistent or long-standing
atrial ﬁbrillation, number of antiarrhythmic drugs failed, and female sex.
Table 3 Freedom from AF after ﬁnal ablation by CAAP-AF score in
the development cohort and the test cohort
CAAP-AF score
Number of AF-free patients/total number of
patients (percentage of AF-free patients)
Development cohort Test cohort
0 4/4 (100%) 4/4 (100%)
1 22/23 (95.7%) 20/23 (86.9%)
2 51/54 (94.4%) 34/38 (89.5%)
3 98/119 (82.4%) 59/64 (92.2%)
4 130/152 (85.5%) 105/116 (90.5%)
5 152/189 (80.4%) 138/161 (85.7%)
6 140/186 (75.3%) 132/175 (75.4%)
7 116/182 (67.4%) 110/148 (74.3%)
8 57/109 (52.3%) 74/109 (67.9%)
9 36/59 (52.2%) 41/60 (68.3%)
10 16/38 (42.1%) 20/29 (69.0%)
11 1/9 (11.1%) 4/10 (40.0%)
12 0/1 (0.00%) None
13 None None
Total 823/1125 (73.2%) 741/937 (79.1%)
AF ¼ atrial ﬁbrillation; CAAP-AF ¼ presence or absence of coronary
artery disease, left atrial diameter, age, presence of persistent or long-
standing atrial ﬁbrillation, number of antiarrhythmic drugs failed, and
female sex.
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obstructive sleep apnea16 is associated with a poor ablation
outcome. We did not ﬁnd sleep apnea to be an independent
predictor of outcome. This may have been due to under-
diagnosis in our patient population. We did not formally
screen patients for obstructive sleep apnea, but instead relied
on their clinical history as to whether they had been given this
diagnosis previously. We also did not try to account for those
patients who had their sleep apnea treated by surgery or by
positive pressure breathing machines. Several studies12–14
have shown that both the CHADS2 and CHA2DS2-VASc
scores are correlated with AF ablation outcome. We did not
include these derived scores in our analysis as they do not
provide independent clinical information. They are each
derived from parameters such as age, sex, left ventricular
dysfunction, hypertension, CAD, and diabetes, all of which
were included individually in our multivariate analysis.
The extent of LA scar, as assessed by delayed enhance-
ment cardiac magnetic resonance imaging (MRI), has also
been shown to predict AF ablation outcome—the greater the
amount of scar, the worse the outcome.20 Those patients with
the lowest amount of LA scar on MRI had a 475-day AF
recurrence rate of 15.3%, and there was a stepwise worsen-
ing outcome as LA scar burden increased. The patients with
the largest amount of LA scar had a 475-day ablation failure
rate of 69.4%. These failure rates are similar to those seen in
our patient cohorts with the lowest, progressing to the
highest CAAP-AF scores. One of the reasons that theCAAP-AF score compares favorably to the predictive value
of a cardiac MRI is that there is probably a strong correlation
between LA scar and LA atrial size. A study by Verma et al21
showed that in patients undergoing AF ablation, more
extensive LA scar as measured by voltage mapping at the
time of ablation was associated with a much poorer ablation
outcome. In that study, the average LA dimension of patients
without LA scar was 4.0 ± 0.8 cm vs a dimension of 4.9 ±
0.7 cm in patients with extensive LA scar. It seems
appropriate that the CAAP-AF score assigns the most points
of any variable to LA size. The simple clinical variables used
in the CAAP-AF score may be more appealing to most
ablationists and medical insurers rather than obtaining an
expensive cardiac MRI, which may be available and
reproducibly measured only at specialized centers. The
parameters in the CAAP-AF score are readily available
preablation and do not depend on ﬁndings obtained only
during ablation, such as extent of LA scar by voltage map,
slowing of AF cycle length, or AF termination by ablation.
The importance of LA scar as a predictor of long-term
outcome is emphasized by a recent publication by Kosiuk
et al.22 The study derived a clinical scoring system to predict
LA scar at the time of ablation. Although the score was
designed to predict the extent of LA scar, it had an excellent
predictive value for long-term outcome of AF ablation, not
only in the population where it was derived but also in a
prospective validation cohort. Several of the predictors of
both LA scar and outcome, namely, larger LA diameter,
older age, and female sex, were the same predictors we found
for the CAAP-AF score.
As the CAAP-AF scores increased, there was a slightly better
freedom from AF in the TC than in the DC. Since the TC under-
went ablation in later years, this modestly improved outcome is
Figure 3 Kaplan-Meier curves for freedom from AF after ﬁnal AF ablation by CAAP-AF score in the development cohort (A) and in the test cohort (B). AF¼
atrial ﬁbrillation; CAAP-AF¼ presence or absence of coronary artery disease, left atrial diameter, age, presence of persistent or long-standing atrial ﬁbrillation,
number of antiarrhythmic drugs failed, and female sex. The vertical axis represents the proportion of patients free of AF at each time interval.
Heart Rhythm, Vol 13, No 11, November 20162124likely related to improvements inmapping, ablation catheters, and
operator experience. We have previously shown that ablation
outcomes improved year by year for both paroxysmal and
persistent AF but not for long-standing persistent AF.23
We do not believe that any single clinical variable or combi-
nation of variables should be the sole determinant of which
patients should undergo AF ablation. Certainly, for those patients
with a low CAAP-AF score, the excellent anticipated freedom
from AF should encourage physicians to recommend that these
patients undergo ablation therapy earlier rather than later. For
patients with high CAAP-AF scores, who are extremely symp-
tomatic or developing left ventricular dysfunction, ablation
therapy may still be appropriate despite a lower likelihood of
success. Although the CAAP-AF score predicted outcome in the
TC quite well, the TC had an overall better outcome than did the
DC despite the TC being a somewhat sicker group with such
factors as older age and more hypertension, diabetes, and
obstructive sleep apnea. This improved outcome likely representsFigure 4 Receiver operating characteristic curves for the CAAP-AF score in th
curve; CAAP-AF¼ presence or absence of coronary artery disease, left atrial diam
antiarrhythmic drugs failed, and female sex; ROC ¼ receiver operating characterithe impact of better ablation technology and ablation experience
in more recent years. The use of this type of scoring system
should help both physicians and patients in deciding whether to
pursue catheter ablation for AF.Study limitations
This was a single-center study. It remains for other centers with
slightly different ablation techniques or experience to verify or
improve upon the CAAP-AF score in their populations.
Patients did not have implantable loop recorders after ablation,
so we undoubtedly missed some episodes of asymptomatic AF.
We have previously examined the recurrence rate of silent AF
in patients we have classiﬁed as free of AF24 after ablation. At
an average of 3.1 years of follow-up, 7-day continuous ECG
monitoring showed that only 4.3% of patients had more than a
30-second episode of atrial arrhythmia and only 1.6% of
patients had an AF burden exceeding 1%. Therefore, our ratee development cohort (A) and in the test cohort (B). AUC ¼ area under the
eter, age, presence of persistent or long-standing atrial ﬁbrillation, number of
stic.
Figure 5 Comparison of 2-year freedom from AF after ﬁnal AF ablation
by CAAP-AF score between the development cohort and the test cohort.
AF¼ atrial ﬁbrillation; CAAP-AF¼ presence or absence of coronary artery
disease, left atrial diameter, age, presence of persistent or long-standing
atrial ﬁbrillation, number of antiarrhythmic drugs failed, and female sex.
2125Winkle et al CAAP-AF Scoreof misclassiﬁed outcomes would appear to be fairly low.
Furthermore, any missed AF should have been distributed
across all CAAP-AF scores and should not inﬂuence the overall
conclusions of our study. The C statistic indicates that there are
probably other unknown variables that contribute to ablation
success in addition to the ones included in the CAAP-AF score.
Nonetheless, the C statistic for the CAAP-AF score is similar to
or better than the C statistic for other commonly used predictive
scoring systems based on clinical variables such as CHADS2
and CHA2DS2-VASc scores.
25 Finally, although our CAAP-
AF score was derived using simple statistical tools compared
with some other predictive scores, virtually all of the other
scores were derived only retrospectively and were not applied
prospectively to a new cohort of similar patients for validation
as we did in the present study. Regardless of how it is derived,
this is the ultimate test of how a score performs.
Conclusion
An easily determined clinical scoring system was derived
retrospectively and applied prospectively. The CAAP-AF
score predicted the ﬁnal freedom from AF after ﬁnal AF
ablation in both a DC and a TC of patients undergoing AF
ablation. The CAAP-AF score provides a realistic expectation
for freedom fromAF following ablation for individual patients.
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